Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | POLG | P54098 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982928 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL207023 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL13262186 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL8345 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL16212282 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL5717505 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL24141674 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL7736439 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL5982921 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| Phosphoric Acid SCHEMBL8409010 | 0.95 | DNMT1 (0.58) | DNMT1ADRB1ALBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285364-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | SERVIER PHARMACEUTICALS LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| US-20180153916-A1 | ISOTOPOLOGUES OF 5-AZACYTIDINE | CELGENE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9693987-B2 | Methods for treating cancers using oral formulations of cytidine analogs | CELGENE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693987-B2 | Methods for treating cancers using oral formulations of cytidine analogs | CELGENE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160250246-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160250246-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2016-09-01 | — | — | US | disclosed |
| US-20150374732-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2015-12-31 | — | — | US | disclosed |
| US-20150374732-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2015-12-31 | — | — | US | disclosed |
| US-20150290228-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2015-10-15 | — | — | US | disclosed |
| US-20150290228-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2015-10-15 | — | — | US | disclosed |
| US-20150216886-A1 | METHODS FOR TREATING CANCERS USING ORAL FORMULATIONS OF CYTIDINE ANALOGS | CELGENE CORP (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150056280-A1 | ISOTOPOLOGUES OF 5-AZACYTIDINE | CELGENE CORPORATION | 2015-02-26 | — | — | US | disclosed |
| US-8846628-B2 | Oral formulations of cytidine analogs and methods of use thereof | CELGENE CORPORATION (US) | 2014-09-30 | — | — | US | disclosed |
| US-8492361-B2 | Methods for treating non-small cell lung cancer using 5-azacytidine | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492361-B2 | Methods for treating non-small cell lung cancer using 5-azacytidine | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130085115-A1 | COMBINATION THERAPY FOR LYMPHOMA | CELGENE CORPORATION (US) | 2013-04-04 | — | — | US | disclosed |
| US-20110319355-A1 | METHODS FOR TREATING NON-SMALL CELL LUNG CANCER USING 5-AZACYTIDINE | PHARMION LLC | 2011-12-29 | — | — | US | disclosed |
| US-20090286752-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285364-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | DHODH, DPYD, DLD | DNMT1 2226/4885ADRB1 2988/4885ALB 4480/4885 |
| US-20150216886-A1 | METHODS FOR TREATING CANCERS USING ORAL FORMULATIONS OF CYTIDINE ANALOGS | CDA, DCTD, DCK | DNMT1 102/4885ADRB1 4626/4885ALB 2377/4885 |
| US-20150056280-A1 | ISOTOPOLOGUES OF 5-AZACYTIDINE | UNG, DCTD, DPYD | DNMT1 13/4885ADRB1 3825/4885ALB 3212/4885 |
| US-20150374732-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | DNMT1 403/4885ADRB1 3992/4885ALB 3033/4885 |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | DNMT1 403/4885ADRB1 3992/4885ALB 3033/4885 |
| US-20090286752-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | DNMT1 403/4885ADRB1 3992/4885ALB 3033/4885 |
| US-20130085115-A1 | COMBINATION THERAPY FOR LYMPHOMA | BCL6, MALT1, HDAC5 | DNMT1 15/4885ADRB1 4830/4885ALB 4642/4885 |
| US-20180153916-A1 | ISOTOPOLOGUES OF 5-AZACYTIDINE | UNG, DCTD, DPYD | DNMT1 13/4885ADRB1 3825/4885ALB 3212/4885 |
| US-20110319355-A1 | METHODS FOR TREATING NON-SMALL CELL LUNG CANCER USING 5-AZACYTIDINE | DCTD, NSUN2, RNMT | DNMT1 15/4885ADRB1 4626/4885ALB 4844/4885 |
| US-20160250246-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | BCL6, BCL3, BCL9 | DNMT1 59/4885ADRB1 4580/4885ALB 1266/4885 |
| US-20150290228-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | BCL6, BCL3, BCL9 | DNMT1 59/4885ADRB1 4580/4885ALB 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.